Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a western diet

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 302, Issue 2, 2012, Pages

  Mells, Jamie E ^a   Fu, Ping P ^a   Sharma, Shvetank ^a   Olson, Darin ^a   Cheng, Lihong ^a   Handy, Jeffrey A ^a   Saxena, Neeraj K ^a   Sorescu, Dan ^a   Anania, Frank A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fatty acid binding protein; Fatty acids; Microsomal triglyceride transfer protein

Indexed keywords

ACYL COENZYME A OXIDASE; COMPLEMENTARY DNA; FATTY ACID; FATTY ACID BINDING PROTEIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HUMAN INSULIN; LIRAGLUTIDE; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; RNA; RNA 18S;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CALORIC INTAKE; CONTROLLED STUDY; DRUG EFFECT; FATTY LIVER; GLUCOSE TOLERANCE TEST; HEART HYPERTROPHY; INSULIN RESISTANCE; INSULIN TOLERANCE TEST; LIPID DIET; LIVER WEIGHT; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADIPOSITY; ANIMALS; CARDIOMEGALY; DIET, HIGH-FAT; FATTY LIVER; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HYPERTENSION; INSULIN RESISTANCE; LIVER; MALE; MICE; MICE, INBRED C57BL;

EID: 84855317103     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00274.2011     Document Type: Article

References (48)

1. Atshaves BP, Martin GG, Hostetler HA, McIntosh AL, Kier AB, Schroeder F. Liver fatty acid-binding protein and obesity. J Nutr Biochem 21: 1015-1032, 2010.
2. Ayala JE, Bracy DP, James FD, Julien BM, Wasserman DH, Drucker DJ. The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology 150: 1155-1164, 2009.
3. Ayala JE, Bracy DP, McGuinness OP, Wasserman DH. Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 55: 390-397, 2006.
4. Binas B, Erol E. FABPs as determinants of myocellular and hepatic fuel metabolism. Mol Cell Biochem 299: 75-84, 2007.
5. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagonlike peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54: 146-151, 2005.
6. Bose AK, Mocanu MM, Carr RD, Yellon DM. Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther 19: 9-11, 2005.
7. Boyle JP, Honeycutt AA, Narayan KM, Hoerger TJ, Geiss LS, Chen H, Thompson TJ. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 24: 1936-1940, 2001.
8. Bruning JC, Michael MD, Winnay JN, Hayashi T, Horsch D, Accili D, Goodyear LJ, Kahn CR. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 2: 559-569, 1998.
9. Chmurzynska A. The multigene family of fatty acid-binding proteins (FABPs): function, structure and polymorphism. J Appl Genet 47: 39-48, 2006.
10. de Piano A, Tock L, Carnier J, Oyama LM, Oller do Nascimento CM, Martinz AC, Foschini D, Sanches PL, Ernandes RM, de Mello MT, Tufik S, Damaso AR. Negative correlation between neuropeptide Y/ agouti-related protein concentration and adiponectinemia in nonalcoholic fatty liver disease obese adolescents submitted to a long-term interdisciplinary therapy. Metabolism 59: 613-619, 2010.
11. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 43: 173-181, 2006.
12. Feldstein AE. Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin Liver Dis 30: 391-401, 2010.
13. Fujita K, Nozaki Y, Wada K, Yoneda M, Fujimoto Y, Fujitake M, Endo H, Takahashi H, Inamori M, Kobayashi N, Kirikoshi H, Kubota K, Saito S, Nakajima A. Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology 50: 772-780, 2009.
14. Gao H, Wang X, Zhang Z, Yang Y, Yang J, Li X, Ning G. GLP-1 amplifies insulin signaling by up-regulation of IRbeta, IRS-1 and Glut4 in 3T3-L1 adipocytes. Endocrine 32: 90-95, 2007.
15. Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, Anania FA. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 51: 1584-1592, 2010.
16. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 291: 2847-2850, 2004.
17. Hostetler HA, Balanarasimha M, Huang H, Kelzer MS, Kaliappan A, Kier AB, Schroeder F. Glucose regulates fatty acid binding protein interaction with lipids and peroxisome proliferator-activated receptor alpha. J Lipid Res 51: 3103-3116, 2010.
18. Hussain MM, Rava P, Pan X, Dai K, Dougan SK, Iqbal J, Lazare F, Khatun I. Microsomal triglyceride transfer protein in plasma and cellular lipid metabolism. Curr Opin Lipidol 19: 277-284, 2008.
19. Irimia JM, Meyer CM, Peper CL, Zhai L, Bock CB, Previs SF, McGuinness OP, DePaoli-Roach A, Roach PJ. Impaired glucose tolerance and predisposition to the fasted state in liver glycogen synthase knock-out mice. J Biol Chem 285: 12851-12861, 2010.
20. Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol 47: 142-156, 2007.
21. Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 28: 360-369, 2008.
22. McClain CJ, Barve S, Deaciuc I. Good fat/bad fat. Hepatology 45: 1343-1346, 2007.
23. Meshkani R, Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem 42: 1331-1346, 2009.
24. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA, Kahn CR. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 6: 87-97, 2000.
25. Minehira K, Young SG, Villanueva CJ, Yetukuri L, Oresic M, Hellerstein MK, Farese RV Jr, Horton JD, Preitner F, Thorens B, Tappy L. Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice. J Lipid Res 49: 2038-2044, 2008.
26. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA 290: 1884-1890, 2003.
27. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 52: 774-788, 2010.
28. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58: 975-983, 2009.
29. Parekh PI, Petro AE, Tiller JM, Feinglos MN, Surwit RS. Reversal of diet-induced obesity and diabetes in C57BL/6J mice. Metabolism 47: 1089-1096, 1998.
30. Petro AE, Cotter J, Cooper DA, Peters JC, Surwit SJ, Surwit RS. Fat, carbohydrate, and calories in the development of diabetes and obesity in the C57BL/6J mouse. Metabolism 53: 454-457, 2004.
31. Qiu W, Taghibiglou C, Avramoglu RK, Van Iderstine SC, Naples M, Ashrafpour H, Mhapsekar S, Sato R, Adeli K. Oleate-mediated stimulation of microsomal triglyceride transfer protein (MTP) gene promoter: implications for hepatic MTP overexpression in insulin resistance. Biochemistry 44: 3041-3049, 2005.
32. Remig V, Franklin B, Margolis S, Kostas G, Nece T, Street JC. Trans fats in America: a review of their use, consumption, health implications, and regulation. J Am Diet Assoc 110: 585-592, 2010.
33. Ricchi M, Odoardi MR, Carulli L, Anzivino C, Ballestri S, Pinetti A, Fantoni LI, Marra F, Bertolotti M, Banni S, Lonardo A, Carulli N, Loria P. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol 24: 830-840, 2009.
34. Samuel VT, Liu ZX, Wang A, Beddow SA, Geisler JG, Kahn M, Zhang XM, Monia BP, Bhanot S, Shulman GI. Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest 117: 739-745, 2007.
35. Sanal MG. The blind men 'see' the elephant-the many faces of fatty liver disease. World J Gastroenterol 14: 831-844, 2008.
36. Sancho V, Nuche B, Arnes L, Cancelas J, Gonzalez N, Diaz-Miguel M, Martin-Duce A, Valverde I, Villanueva-Penacarrillo ML. The action of GLP-1 and exendins upon glucose transport in normal human adipocytes, and on kinase activity compared with morbidly obese patients. Int J Mol Med 19: 961-966, 2007.
37. Sancho V, Trigo MV, Gonzalez N, Valverde I, Malaisse WJ, Villanueva-Penacarrillo ML. Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats. J Mol Endocrinol 35: 27-38, 2005.
38. Saxena NK, Titus MA, Ding X, Floyd J, Srinivasan S, Sitaraman SV, Anania FA. Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation. FASEB J 18: 1612-1614, 2004.
39. Schroeder F, Petrescu AD, Huang H, Atshaves BP, McIntosh AL, Martin GG, Hostetler HA, Vespa A, Landrock D, Landrock KK, Payne HR, Kier AB. Role of fatty acid binding proteins and long chain fatty acids in modulating nuclear receptors and gene transcription. Lipids 43: 1-17, 2008.
40. Sharma S, Mells JE, Fu PP, Saxena NK, Anania FA. GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One 6: e25269, 2011.
41. Shindo N, Fujisawa T, Sugimoto K, Nojima K, Oze-Fukai A, Yoshikawa Y, Wang X, Yasuda O, Ikegami H, Rakugi H. Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model. J Hepatol 52: 903-912, 2010.
42. Shlomo SB, Zvibel I, Shnell M, Shlomai A, Chepurko E, Halpern Z, Barzilai N, Oren R, Fishman S. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol 54: 1214-1223, 2011.
43. Sozio MS, Liangpunsakul S, Crabb D. The role of lipid metabolism in the pathogenesis of alcoholic and nonalcoholic hepatic steatosis. Semin Liver Dis 30: 378-390, 2010.
44. Surwit RS, Wang S, Petro AE, Sanchis D, Raimbault S, Ricquier D, Collins S. Diet-induced changes in uncoupling proteins in obesity-prone and obesity-resistant strains of mice. Proc Natl Acad Sci USA 95: 4061-4065, 1998.
45. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 295: G987-G995, 2008.
46. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol 5: 145-171, 2010.
47. Wetterau JR, Lin MC, Jamil H. Microsomal triglyceride transfer protein. Biochim Biophys Acta 1345: 136-150, 1997.
48. Xie Y, Newberry EP, Young SG, Robine S, Hamilton RL, Wong JS, Luo J, Kennedy S, Davidson NO. Compensatory increase in hepatic lipogenesis in mice with conditional intestine-specific Mttp deficiency. J Biol Chem 281: 4075-4086, 2006.